NCT07182552

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

• Status: Enrolling By Invitation
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical · Industry
• Sex: All
• Age: 25 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.

Detailed description

This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.

Conditions

• TED

Interventions

Type	Name	Description
DRUG	NTB003	NTB003 dose 1, dose 2, dose 3, dose 4
DRUG	Placebo	Placebo dose 1, dose 2, dose 3, dose 4

Timeline

• Start date: 2025-06-30
• Primary completion: 2026-02-23
• Completion: 2026-03-30
• First posted: 2025-09-19
• Last updated: 2025-09-19

Locations

1 site across 1 country: China